Evaluation of recurrent parasitemia after artemether-lumefantrine treatment for uncomplicated malaria in children in western Kenya
From April 2005 to April 2006, a phase 2 malaria vaccine trial in Kenya enrolled 400 children aged 12-47 months. Each received mixed supervised and unsupervised artemether-lumefantrine for uncomplicated malaria, using a standard six-dose regimen, by weight. Children were followed for detection of parasitemia and clinical malaria. A median of two negative malaria blood films occurred during every recurrent parasitemia (RP) episode, suggesting reinfection over late recrudescence. Median time to RP after starting artemether-lumefantrine was 37 days (36-38). Of 2,020 evaluable artemether-lumefantrine treatments, there were no RPs in 99% by day 14, 71% by day 28, and 41% by day 42. By World Health Organization standards, 71% of treatment courses had adequate responses. Although recrudescence in some cannot be ruled out, our cohort had a shorter median time to RP compared with other artemether-lumefantrine treatment studies. This underscores patient counseling on completing all treatment doses for optimal protection from RP.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
The American journal of tropical medicine and hygiene - 83(2010), 3 vom: 15. Sept., Seite 458-64 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Woodring, Joseph V [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.09.2010 Date Revised 20.10.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4269/ajtmh.2010.09-0403 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM201286254 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM201286254 | ||
| 003 | DE-627 | ||
| 005 | 20231223222138.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4269/ajtmh.2010.09-0403 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0671.xml |
| 035 | |a (DE-627)NLM201286254 | ||
| 035 | |a (NLM)20810804 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Woodring, Joseph V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of recurrent parasitemia after artemether-lumefantrine treatment for uncomplicated malaria in children in western Kenya |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.09.2010 | ||
| 500 | |a Date Revised 20.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a From April 2005 to April 2006, a phase 2 malaria vaccine trial in Kenya enrolled 400 children aged 12-47 months. Each received mixed supervised and unsupervised artemether-lumefantrine for uncomplicated malaria, using a standard six-dose regimen, by weight. Children were followed for detection of parasitemia and clinical malaria. A median of two negative malaria blood films occurred during every recurrent parasitemia (RP) episode, suggesting reinfection over late recrudescence. Median time to RP after starting artemether-lumefantrine was 37 days (36-38). Of 2,020 evaluable artemether-lumefantrine treatments, there were no RPs in 99% by day 14, 71% by day 28, and 41% by day 42. By World Health Organization standards, 71% of treatment courses had adequate responses. Although recrudescence in some cannot be ruled out, our cohort had a shorter median time to RP compared with other artemether-lumefantrine treatment studies. This underscores patient counseling on completing all treatment doses for optimal protection from RP | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 7 | |a Antimalarials |2 NLM | |
| 650 | 7 | |a Artemether, Lumefantrine Drug Combination |2 NLM | |
| 650 | 7 | |a Artemisinins |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Ethanolamines |2 NLM | |
| 650 | 7 | |a Fluorenes |2 NLM | |
| 650 | 7 | |a Malaria Vaccines |2 NLM | |
| 700 | 1 | |a Ogutu, Bernhards |e verfasserin |4 aut | |
| 700 | 1 | |a Schnabel, David |e verfasserin |4 aut | |
| 700 | 1 | |a Waitumbi, John N |e verfasserin |4 aut | |
| 700 | 1 | |a Olsen, Cara H |e verfasserin |4 aut | |
| 700 | 1 | |a Walsh, Douglas S |e verfasserin |4 aut | |
| 700 | 1 | |a Heppner, D Gray |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Polhemus, Mark E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The American journal of tropical medicine and hygiene |d 1945 |g 83(2010), 3 vom: 15. Sept., Seite 458-64 |w (DE-627)NLM000012513 |x 1476-1645 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2010 |g number:3 |g day:15 |g month:09 |g pages:458-64 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4269/ajtmh.2010.09-0403 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2010 |e 3 |b 15 |c 09 |h 458-64 | ||